A helmet up for auction in London is a well-preserved example of the "Corinthian" helmets used by many hoplite warriors. A rare "Corinthian" helmet from ancient Greece will go up for auction in ...

The FDA recently approved Journavx for treating acute pain. This approval is tremendously important for Vertex Pharmaceuticals. The biotech company has also received other good news over the last ...

Vertex just won approval for a drug to treat one of the most common health problems -- pain. The biotech company is offering an option for patients and doctors who don’t want to go for ...

Motorcycle helmets have come a long way over the years. They had humble beginnings in the early 1900s with limited protection for riders and no other features to speak of. Today's options have ...

You only have one brain and so it’s important to buy the best motorbike helmet you can afford. That doesn’t always mean spending £1000+ on a race-ready carbon lid, though, and there are ...

HOUSTON, January 22, 2025--(BUSINESS WIRE)--Vertex Energy, Inc. ("Vertex" or the "Company"), a leading specialty refiner and marketer of high-quality refined products, together with its affiliates ...

If you were leafing through climbing magazines in the 90’s and early aughts you might have thought that helmets weren’t a thing in climbing. The epic photos of climbers posing on the side of cliffs ...

UnitedHealthcare likely to cover Vertex’s pain drug Vertex Pharmaceuticals received FDA approval for a new non-opioid pain drug, marketed as Journavx, and it appears the nation’s largest ...

A helmet has one job and is designed to do it exactly once. But there’s dozens of different ways to accomplish this. Whether you’re hitting triple digits at the track or tackling muddy ruts in ...

Gateway Safety has redesigned its Serpent® safety helmet. With a fresh, sleek shell design, the popular helmet line now includes an unvented Class E model, and Serpent is now available in several ...

Scotiabank raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $450 from $433 and keeps a Sector Perform rating on the shares. The company had a strong Q4, with revenue beating ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...